Joshua Ismin is CEO/co-founder of Psylo with diverse commercial and operational experience across a range of start-ups. Josh is an exited founder with extensive fundraising experience, and is an active early-stage investor. He holds an MBA and BSBA from Washington University in St Louis.

Psylo is a small molecule biotech start-up developing next-generation therapeutics inspired by psychedelic compounds that exist in nature.  Psylo is targeting the 5-HT2A receptor for the treatment of neuropsychiatric conditions based on the emerging promise of psilocybin.  Our mission is to produce novel take-home medications which extend the healing potential of psychedelics to a broader patient population.